TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03526692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
Study: NCT00740818

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No Intervention
Description: The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Logan Basic Adjustment
Description: A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic adjustment
Description: Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
Study: NCT01860794

Intervention type: DRUG
Group type: OTHER
Intervention: Mesencephalic Neuronal Precursor Cells
Description: All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
Study: NCT01468844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg pink opaque capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study: NCT02184390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On LIne Parent Training Tutorial
Description: Interactive on line tutorial for parenting skills for autism
Study: NCT03944551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Therapy
Description: For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
Study: NCT00758004

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single dose of 80 mg atrovastatin tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin pediatric appropriate formulation
Description: A single dose of pediatric appropriate atorvastatin 80 mg formulation
Study: NCT04191694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron 4 MG
Description: Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
Study: NCT03261739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYI-018
Description: Anti-CB1 monoclonal antibody
Study: NCT00298623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 (GSK1838262)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02675751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR S4 IR laser with iDesign
Description: Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
Study: NCT02832557

Intervention type: OTHER
Intervention: Salivary collection
Description: Collection of saliva via swab for miRNA processing

Intervention type: OTHER
Intervention: Vineland Adaptive Behavior Scale-III Assessment

Intervention type: OTHER
Intervention: Medical history questionaire

Intervention type: OTHER
Intervention: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)

Intervention type: OTHER
Intervention: Mullen Scales of Early Learning
Study: NCT00443053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux 2.5mg or placebo
Description: Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fondaparinux 2.5mg or placebo
Description: Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
Study: NCT02620878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial pancreas
Description: Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump
Description: During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
Study: NCT02441153

Intervention type: OTHER
Intervention: Extended Timing
Description: Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
Study: NCT02991495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril, Sanofi Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril, Sanofi Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Bio-Manguinhos
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Bio-Manguinhos
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Institut Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study: NCT00193791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT + RT
Description: Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
Study: NCT04433637

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cake + fruit juice
Description: Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
Study: NCT04224714

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FFR
Description: FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
Study: NCT03763656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hydroxyurea (100 mg/mL) Solution
Description: Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
Study: NCT01191645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Description: Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
Study: NCT01402557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Church Program
Description: An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Church Program
Description: An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Following completion of the weight loss program, participants will receive monthly telephone counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Following completion of the weight loss program, participants will receive monthly telephone counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Support
Description: After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
Study: NCT01644669

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative Radiation Therapy - IORT
Description: Single dose of 20 Gy
Study: NCT02242214

Intervention type: DRUG
Intervention: Misoprostol
Study: NCT01518686

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)
Description: We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)
Study: NCT02358200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN-673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01519687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levotofisopam
Description: 50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
Study: NCT03654924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask
Description: General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
Study: NCT03315793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04120883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine lower dose
Description: The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine higher dose
Description: The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
Study: NCT04433637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
Study: NCT03640325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM (Promoting Resilience in Stress Management)
Description: Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
Study: NCT04785534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: Undergo clinical evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Ultrasonographic Elastography
Description: Undergo fibroscan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT03415594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE203799 GLP-2 analogue
Description: FE203799 5 mg subQ once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FE203799 Placebo GLP-2 analogue
Description: Placebo subQ once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: FE203799 GLP-2 analogue
Description: FE203799 10 mg subQ once weekly
Study: NCT01575639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
Study: NCT03261739

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04216511

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor autoantibody detection
Description: Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
Study: NCT02482428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara
Description: Applied 3 times a week for 16 weeks
Study: NCT01238991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
Study: NCT03051880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repair Control EGF®
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream without rhEGF
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study: NCT00617084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Endeavor Resolute
Description: Medtronic Endeavor Resolute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Xience V
Description: Abbott Xience V
Study: NCT00042952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study: NCT04080349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200Mcg Tab
Description: 1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Study: NCT03271944

Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 Laser Treatment
Description: Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
Study: NCT00042952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00778297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FluvalAB FL-K-004 trivalent flu vaccine
Description: Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with FluvalAB trivalent influenza vaccine
Description: Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).